Research Analysts’ Weekly Ratings Changes for TRex Bio (TRXB)

TRex Bio (NASDAQ: TRXB) recently received a number of ratings updates from brokerages and research firms:

• 11/3/2026 – TRex Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 11/3/2026 – TRex Bio is now covered by Stifel Nicolaus. They set a “buy” rating and a $39.00 price target on the stock.
• 11/3/2026 – TRex Bio is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $20.00 price target on the stock.
• 11/2/2026 – TRex Bio is now covered by Wedbush. They set an “outperform” rating and a $30.00 price target on the stock.

TRex Bio Trading Down 1.9%

Shares of TRex Bio stock traded down $0.26 on Wednesday, hitting $13.38. 53,979 shares of the company’s stock traded hands, compared to its average volume of 103,035. TRex Bio, Inc. has a 52-week low of $13.10 and a 52-week high of $16.56.

Insider Transactions at TRex Bio

In related news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the acquisition, the insider directly owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. The trade was a 15.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.